Overview

Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome

Status:
Completed

Trial end date:
2016-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether HemaMax is safe and well tolerated to support efficacy under FDA's Animal Rule to reduce the morbidity and mortality associated with the hematopoietic syndrome of acute radiation syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Neumedicines Inc.

Collaborator:

Department of Health and Human Services